Factor VII
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Coagulation factor VII (serum prothrombin conversion accelerator)
| ||||||||||||||
| | ||||||||||||||
| Anchoring of coagulation factor VIIa to the mebrane through its Gla domain | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | F7; | |||||||||||||
| External IDs | OMIM: 227500 MGI: 109325 Homologene: 7710 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 2155 | 14068 | ||||||||||||
| Ensembl | ENSG00000057593 | ENSMUSG00000031443 | ||||||||||||
| Uniprot | P08709 | Q542C2 | ||||||||||||
| Refseq | NM_000131 (mRNA) NP_000122 (protein) | NM_010172 (mRNA) NP_034302 (protein) | ||||||||||||
| Location | Chr 13: 112.81 - 112.82 Mb | Chr 8: 13.03 - 13.04 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
|
WikiDoc Resources for Factor VII | |
|
Articles | |
|---|---|
|
Most recent articles on Factor VII | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Factor VII at Clinical Trials.gov Clinical Trials on Factor VII at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Factor VII
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Factor VII Discussion groups on Factor VII Patient Handouts on Factor VII Directions to Hospitals Treating Factor VII Risk calculators and risk factors for Factor VII
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Factor VII | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Factor VII (formerly known as proconvertin) is one of the central proteins in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class.
Physiology
The main role of factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels - normally not exposed to the bloodstream. Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), activated factor X and the FVIIa-TF complex itself. The most important substrates for FVIIa-TF are Factor X and Factor IX.
The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants impairs its function.
Genetics
The gene for factor VII is located on chromosome 13 (13q34).
Role in disease
Deficiency is rare (congenital proconvertin deficiency) and inherits recessively.
Therapeutic use
Recombinant human factor VIIa (NovoSeven®, eptacog alfa [activated], ATC code B02BD08) has been introduced for use in uncontrollable bleeding in hemophilia patients (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.
It is being increasingly used in uncontrollable hemorrhage.[1] The first report of its use was in an Israeli soldier with uncontrollable bleeding in 1999.[1] The rationale for its use in hemorrhage is, that it will only induce coagulation in those sites where tissue factor (TF) is also present. Still, O'Connell et al report an increased risk of deep vein thrombosis, pulmonary embolism and myocardial infarction in association with the use of rhFVIIa.[1]
According to a 2005 study, recombinant human factor VII improves outcomes in acute intracerebral hemorrhage.[1]
References
External links
Further reading
- Versteeg HH, Peppelenbosch MP, Spek CA (2002). "The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?". Thromb. Haemost. 86 (6): 1353-9. PMID 11776298.
- Golino P (2003). "The inhibitors of the tissue factor:factor VII pathway.". Thromb. Res. 106 (3): V257-65. PMID 12356487.
Proteins: coagulation | |
|---|---|
| Coagulation factors | intrinsic pathway (FXII, FXI, FIX, FVIII) - extrinsic pathway (Tissue factor, FVII) - common pathway (FX, FV, (Pro)thrombin / FII, Fibrin / FI, FXIII) - HMWK - vWF - Kallikrein |
| Inhibitors | Antithrombin - Protein C - Protein S - Protein Z - ZPI - TFPI |
| Fibrinolysis | Plasmin - tPA/urokinase - PAI-1/2 - α2-AP - α2-macroglobulin - TAFI |
Antihemorrhagics (B02) | |
|---|---|
| Antifibrinolytics | amino acids (Aminocaproic acid, Tranexamic acid, Aminomethylbenzoic acid) - serpins (Aprotinin, Alfa1 antitrypsin, C1-inhibitor, Camostat) |
| Vitamin K | Phytomenadione - Menadione |
| Fibrinogen | Fibrinogen |
| Local hemostatics | Absorbable gelatin sponge - Oxidized cellulose - Tetragalacturonic acid hydroxymethylester - Adrenalone - Thrombin - Collagen - Calcium alginate - Epinephrine |
| Blood coagulation factors | IX - II - VII - X - VIII - Eptacog alfa - Nonacog alfa - Thrombin |
| Other systemic hemostatics | Etamsylate - Carbazochrome - Batroxobin |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

